Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:51:38 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:BMRN - BIOMARIN PHARMACEUTICAL - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BMRN - Q0.457.21·64.170.258.13+0.981.71,643.594,42016,70457.26  58.43  57.2673.51  50.7619:34:50Jan 2915 min RT 2¢

Recent Trades - Last 10 of 16704
Time ETExPriceChangeVolume
19:34:50Q57.500.351
19:33:12Q58.000.851
18:47:26Q58.25131.101310
18:17:08Q58.251.103
17:11:33Q57.980.8310
16:47:00Q57.700.553
16:20:00Q58.130.983,384
16:10:04Q58.130.981
16:10:04Q58.130.981
16:10:04Q58.130.981

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-29 16:05U:BMRNNews ReleaseBioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
2026-01-26 07:45U:BMRNNews ReleaseBioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
2026-01-12 16:05U:BMRNNews ReleaseBioMarin Appoints Arpit Dave Chief Digital and Information Officer
2026-01-08 16:05U:BMRNNews ReleaseBioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
2026-01-08 08:30U:BMRNNews ReleaseVeeva and BioMarin Form Long-Term Strategic Partnership
2025-12-19 07:45U:BMRNNews ReleaseBioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
2025-11-11 09:00U:BMRNNews ReleaseBioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
2025-10-29 09:00U:BMRNNews ReleaseFDA Accepts BioMarin's PALYNZIQ(TM) (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
2025-10-27 16:03U:BMRNNews ReleaseBioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
2025-10-22 16:05U:BMRNNews ReleaseBioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
2025-09-08 09:00U:BMRNNews ReleaseBioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
2025-09-06 11:05U:BMRNNews ReleaseBioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ(TM) (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
2025-08-27 09:00U:BMRNNews ReleaseBioMarin to Participate in Upcoming Investor Conferences
2025-08-04 16:02U:BMRNNews ReleaseBioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance Superscript 1 for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
2025-08-01 09:00U:BMRNNews ReleaseBioMarin Announces Appointment of Ian T. Clark to Board of Directors
2025-07-22 09:00U:BMRNNews ReleaseBioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
2025-07-01 08:45U:BMRNNews ReleaseBioMarin Announces Completion of Acquisition of Inozyme
2025-06-24 09:00U:BMRNNews ReleaseBioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN(TM) (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
2025-05-16 07:30U:BMRNNews ReleaseBioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
2025-05-12 09:05U:BMRNNews ReleaseBioMarin Presents New Data for VOXZOGO(TM) (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings